Cargando…

Levoketoconazole treatment in endogenous Cushing’s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes

OBJECTIVE: This extended evaluation (EE) of the SONICS study assessed the effects of levoketoconazole for an additional 6 months following open-label, 6-month maintenance treatment in endogenous Cushing’s syndrome. DESIGN/METHODS: SONICS included dose-titration (150–600 mg BID), 6-month maintenance,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fleseriu, Maria, Auchus, Richard J, Greenman, Yona, Zacharieva, Sabina, Geer, Eliza B, Salvatori, Roberto, Pivonello, Rosario, Feldt-Rasmussen, Ulla, Kennedy, Laurence, Buchfelder, Michael, Biller, Beverly MK, Cohen, Fredric, Heaney, Anthony P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bioscientifica Ltd 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716395/ https://www.ncbi.nlm.nih.gov/pubmed/36251618 http://dx.doi.org/10.1530/EJE-22-0506

Ejemplares similares

SAT-452 Results from the Phase 3 Multicenter SONICS Study of Levoketoconazole: Subgroup Analysis of Cushing's Syndrome (CS) Patients with Diabetes Mellitus (DM)
por: Fleseriu, Maria, et al.
Publicado: (2019)

Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
por: Geer, Eliza B., et al.
Publicado: (2020)

Correction to: Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing’s syndrome
por: Geer, Eliza B., et al.
Publicado: (2020)

Levoketoconazole in the Treatment of Patients With Cushing’s Syndrome and Diabetes Mellitus: Results From the SONICS Phase 3 Study
por: Pivonello, Rosario, et al.
Publicado: (2021)

Levoketoconazole in the treatment of patients with endogenous Cushing’s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS)
por: Pivonello, Rosario, et al.
Publicado: (2022)

MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study
por: Zacharieva, Sabina Z, et al.
Publicado: (2020)

Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal Study
por: Zacharieva, Sabina, et al.
Publicado: (2021)

COVID-19 and Cushing's syndrome: recommendations for a special population with endogenous glucocorticoid excess
por: Pivonello, Rosario, et al.
Publicado: (2020)

PMON160 Improvements in Clinical Signs of Hypercortisolism and Quality of Life According to Urinary and Late-Night Salivary Cortisol Levels in Patients with Cushing's Disease Treated with Osilodrostat
por: Biller, Beverly M K, et al.
Publicado: (2022)

Treatment of Cushing’s syndrome with osilodrostat: practical applications of recent studies with case examples
por: Fleseriu, Maria, et al.
Publicado: (2022)

Long-term outcomes of osilodrostat in Cushing’s disease: LINC 3 study extension
por: Fleseriu, Maria, et al.
Publicado: (2022)

OR16-2 Osilodrostat Treatment in Cushing's Disease (CD): Results from a Phase III, Multicenter, Double-Blind, Randomized Withdrawal Study (LINC 3)
por: Biller, Beverly MK, et al.
Publicado: (2019)

THU041 Clinical Improvements In Patients With Cushing’s Disease Treated With Osilodrostat According To Urinary And Late-night Salivary Cortisol Levels: Pooled Analysis From LINC 3 And LINC 4
por: Biller, Beverly M K, et al.
Publicado: (2023)

Long-Term Control of Urinary Free Cortisol With Osilodrostat in Patients With Cushing’s Disease: Final Results From the LINC 2 Study
por: Fleseriu, Maria, et al.
Publicado: (2021)

Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study
por: Findling, James W., et al.
Publicado: (2016)

Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing’s disease
por: Fleseriu, Maria, et al.
Publicado: (2015)

THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
por: Newell-Price, John, et al.
Publicado: (2023)

Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease
por: Newell-Price, John, et al.
Publicado: (2019)

PMON163 Effect of Osilodrostat on Androgens and Adrenal Hormones in Patients With Cushing's Disease: Long-Term Findings From the Phase III, Prospective LINC 3 Study
por: Fleseriu, Maria, et al.
Publicado: (2022)

Long-term efficacy and safety of osilodrostat in Cushing’s disease: final results from a Phase II study with an optional extension phase (LINC 2)
por: Fleseriu, Maria, et al.
Publicado: (2022)

Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome
por: He, Xin, et al.
Publicado: (2022)

Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing’s disease
por: Feelders, Richard A., et al.
Publicado: (2023)

Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas
por: Biller, Beverly MK, et al.
Publicado: (2010)

THU032 Osilodrostat Is Effective And Well Tolerated In Patients Of Asian And Non-Asian Origin With Cushing's Disease: A Pooled Analysis From LINC 3 And LINC 4
por: Snyder, Peter J, et al.
Publicado: (2023)

The dopaminergic control of Cushing’s syndrome
por: Pivonello, R., et al.
Publicado: (2022)

Hypercoagulability and Risk of Venous Thromboembolic Events in Endogenous Cushing's Syndrome: A Systematic Meta-Analysis
por: Wagner, Jeffrey, et al.
Publicado: (2019)

LBMON177 Dosing And Titration Of Osilodrostat In A Real-world Cohort Of US Patients With Endogenous Cushing's Disease: Analysis Of The ILLUSTRATE Study
por: Ioachimescu, Adriana Gabriela, et al.
Publicado: (2022)

Recent advances in the medical treatment of Cushing’s disease
por: Fleseriu, Maria
Publicado: (2014)

Evaluating the burden of endogenous Cushing’s syndrome using a web-based questionnaire and validated patient-reported outcome measures
por: Page-Wilson, Gabrielle, et al.
Publicado: (2023)

Medical management of Cushing’s disease: what is the future?
por: Fleseriu, Maria, et al.
Publicado: (2012)

Pituitary-Directed Therapies for Cushing’s Disease
por: Langlois, Fabienne, et al.
Publicado: (2018)

Neuropsychiatric disorders in Cushing's syndrome
por: Pivonello, Rosario, et al.
Publicado: (2015)

Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study
por: Fleseriu, Maria, et al.
Publicado: (2019)

Cushing’s disease: adrenal steroidogenesis inhibitors
por: Pivonello, Rosario, et al.
Publicado: (2022)

Salivary Cortisol in the Diagnosis of Cushing Syndrome, Always More Than One!
por: Fleseriu, Maria
Publicado: (2020)

Update on medical treatment for Cushing’s disease
por: Cuevas-Ramos, Daniel, et al.
Publicado: (2016)

Perioperative Management of a Patient With Cushing Disease
por: Varlamov, Elena V, et al.
Publicado: (2022)

Mifepristone Improves Octreotide Efficacy in Resistant Ectopic Cushing's Syndrome
por: Moraitis, Andreas G., et al.
Publicado: (2016)

Invasive fungal infections in endogenous Cushing's syndrome
por: Scheffel, Rafael Selbach, et al.
Publicado: (2010)

Randomized Trial of Osilodrostat for the Treatment of Cushing Disease
por: Gadelha, Mônica, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_57ei25e2uav24j7iias23jo5ou